Ligand to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced today that Ligand management is scheduled to present at the following upcoming investor conferences:
Deutsche Bank 38th Annual dbAccess Health Care Conference in Boston, MA. Presentation: Wednesday, May 29, 2013 at 8:00 a.m. Eastern (5:00 a.m. Pacific).
Jefferies 2013 Global Healthcare Conference in New York, NY. Presentation: Tuesday, June 4, 2013 at 11:00 a.m. Eastern (8:00 a.m. Pacific).
A live webcast of these presentations will be available on Ligand's website at www.ligand.com. A replay of the presentations will be archived there for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand's Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly & Co., Spectrum Pharmaceuticals and The Medicines Company. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.
Follow Ligand on Twitter @Ligand_LGND.
KEYWORDS: United States North America California Massachusetts New York
The article Ligand to Present at Upcoming Investor Conferences originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.